Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study With Expansion Cohorts Evaluating the Safety and Efficacy of Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

NCT05464329 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05464329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05464329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study With Expansion Cohorts Evaluating the Safety and Efficacy of Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 3, 2023
Completion date
October 16, 2029
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma grade 3b, high-grade b-cell lymphoma, large b-cell lymphoma, transformed b-cell lymphoma